Neola Medical continues to advance through the clinical phase, with its clinical pilot study on preterm born babies in Sweden now at the halfway point. During the autumn, the company strengthened its leadership team with the appointment of a Clinical Director, expanded its intellectual property portfolio with a new European patent, and CEO Hanna Sjöström participated in the Stanford Impact1 CEO Summit, further building Neola Medical’s international network of leading clinicians, experts, and investors as the company advances toward market authorization.
“Strengthening our leadership team, expanding our patent portfolio, and deepening our international network through Stanford Impact1 are all important steps as we advance toward market authorization and continue our mission to improve outcomes for preterm born babies,” says CEO Hanna Sjöström.
Read more in the investor letter autumn 2025, attached to this press release and available on the company’s website www.neolamedical.com